As pharmacists, we see the effect of every guideline change at the medicines optimisation stage. Two UK developments in 2026 will change the work of prescribers and nurses, both in the community and on the wards.
The first is NICE’s revised type 2 diabetes guideline (NG28), published on 18 February 2026. It moves cardiorenal protection to the start of treatment. Many more patients will now arrive in hospital already taking an SGLT-2 inhibitor or a weekly GLP-1 injection. The second is the NHS England hybrid closed loop programme, which has now passed its two-year mark. It is moving from children to adults with type 1 diabetes, so more adults will be admitted wearing an insulin pump and sensor.
This article summarises both changes and sets out the points we think matter most. It covers starting treatment in primary care, managing patients during a hospital admission and safe discharge.
What has changed in NICE NG28 (February 2026)
| Area | Previous approach | 2026 recommendation |
| First-line therapy | Metformin monotherapy, with SGLT-2 inhibitors added by risk | Metformin plus an SGLT-2 inhibitor (dapagliflozin or empagliflozin) from diagnosis |
| Metformin formulation | Standard release | Modified-release (MR) metformin as standard |
| GLP-1 receptor agonists and tirzepatide | Narrower criteria | Recommended for people with atherosclerotic cardiovascular disease, onset before age 40, or obesity |
NICE estimates the update could prevent about 17,000 deaths over three years. It also expects about 810,000 more people to become eligible for a GLP-1 receptor agonist (semaglutide, dulaglutide, liraglutide) or tirzepatide.
From a pharmacy perspective, the message is simple: the first prescription for newly diagnosed type 2 diabetes is now usually two medicines, not one. That doubles the counselling at the point of diagnosis. The quality of the first conversation will largely decide adherence and safety.
Prescribing SGLT-2 inhibitors at diagnosis
Before initiating
Before starting an SGLT-2 inhibitor, check renal function, volume status and current diuretic use. Older patients on loop diuretics are at particular risk of volume depletion.
Ask about very low-carbohydrate or ketogenic diets, heavy alcohol use and any history of DKA, as all of these raise ketoacidosis risk. Remember that glycaemic efficacy falls as eGFR declines, although cardiorenal benefit is retained. Check the SmPC for current initiation thresholds.
Counselling we ask prescribers to reinforce
Sick day rules come first. Patients should pause the SGLT-2 inhibitor during acute illness, vomiting, diarrhoea or reduced oral intake and restart once eating and drinking normally.
Patients also need to understand euglycaemic DKA. They should know the symptoms (nausea, vomiting, abdominal pain, breathlessness, malaise) and that blood glucose may look near normal.
For peri-operative interruption, withhold the medicine before major surgery or procedures that need fasting, in line with the local peri-operative policy. Genital mycotic infection is common. Advice on hygiene helps and so does early recognition.
Prescribing modified-release (MR) metformin
MR metformin is now the standard choice. This helps reduce gastrointestinal side effects and also allows for once-daily dosing, improving compliance and tablet burden. Ensure the patient is aware of the formulation change when switching.
MR metformin is usually given once daily with the evening meal, so consolidate the dosing when you switch.
Keep reviewing renal function and B12 status during long-term therapy, as before.
Prescribing GLP-1 receptor agonists and tirzepatide
When adding a GLP-1 receptor agonist or tirzepatide to insulin or a sulfonylurea, consider reducing the dose of those agents because of the hypoglycaemia risk with combination therapy. Advise patients to monitor blood glucose more often during titration.
Gastrointestinal tolerability matters too, as nausea is the main reason people stop treatment. Titrate as the SmPC directs and do not rush dose escalation. Advise smaller meals and stopping eating once full.
Tirzepatide may reduce the effectiveness of oral contraceptives. The MHRA advises adding a barrier method, or switching to a non-oral method, for four weeks after starting and after each dose increase. GLP-1 receptor agonists and tirzepatide should not be used in pregnancy.
Consider delayed gastric emptying before procedures that need sedation or anaesthesia and for oral drugs with a narrow therapeutic index. Asphyxiation can be a risk during surgery. Finally, check that patients can use their pen correctly, know their weekly dosing day and know what to do after a missed dose.
Hybrid closed loop systems (the artificial pancreas) and what healthcare teams need to know
How a hybrid closed loop system works
The hybrid closed loop (HCL) system, often called an artificial pancreas, connects three parts:
- A continuous glucose monitor (CGM) reads interstitial glucose every few minutes.
- A control algorithm, in the pump or on a smartphone, predicts where glucose is heading.
- An insulin pump then increases, reduces or suspends rapid-acting insulin delivery.
The cycle repeats continuously, day and night. It is called “hybrid” because the user still enters mealtime carbohydrates so the system can give a bolus. The automation works best overnight and between meals, which is where it has the most effect on hypoglycaemia and glycaemic variability.
The NHS hybrid closed loop rollout so far
NHS England began a five-year rollout in April 2024, following NICE technology appraisal TA943. Eligible groups are:
- Children and young people under 18 with type 1 diabetes.
- People with type 1 diabetes who are pregnant or planning a pregnancy.
- Adults with an HbA1c of 58 mmol/mol (7.5%) or higher, or disabling hypoglycaemia, who already use a pump or a CGM.
The two-year results in children and young people (May 2026) are striking:
| Measure | At launch | May 2026 |
| Uptake (children and young people) | 43% | 73% |
| Median HbA1c (mmol/mol) | 58 | 55.5 |
| Meeting target of 48 mmol/mol or lower | 15.4% | 19.2% |
| HbA1c above 69 mmol/mol | 21.1% | 14.9% |
| DKA admission (not at diagnosis) | 0.8% | 0.4% |
Uptake across all ages is still only 18%. The remaining three years of the programme focus on adults, supported by a national adoption programme launched in April 2026.
What hybrid closed loop means in primary care
Adults who meet the eligibility criteria should be referred to their specialist diabetes service. Practice searches for type 1 patients with an HbA1c of 58 mmol/mol or higher are a quick win.
Keep the backup on repeat. Every HCL user still needs insulin pens (basal and rapid-acting), pen needles, blood glucose strips and blood ketone strips. Pump or sensor failure is not unusual and without a backup a technical fault can become a DKA admission. Please do not remove these items as “no longer needed”.
Pump consumables and sensors are often supplied through specialist or ICB arrangements rather than FP10, so check local pathways before adding device items to repeat templates. HCL users should also have a written sick day plan from their specialist team, including when to check ketones and when to switch to pen injections.
Device settings stay with the specialist team. Primary care and community pharmacy can do the most by safeguarding supplies, checking adherence and escalating promptly.
Managing diabetes medicines and hybrid closed loop systems in hospital
More patients will now be admitted on SGLT-2 inhibitors, weekly GLP-1 injections and hybrid closed loop systems. The points below are for prescribers, nurses and pharmacists on the wards, in theatres and in emergency departments. Always follow your trust’s inpatient diabetes policy and the Joint British Diabetes Societies for Inpatient Care (JBDS-IP) guidance and involve the inpatient diabetes team early.
Medicines reconciliation on admission
Record every glucose-lowering medicine, including weekly injections. For any weekly injection, record the day and date of the last dose, as these are easily missed on drug histories.
Ask whether the patient wears a pump or a sensor and which one. Note who manages the device (the patient, a carer or nobody) and where the backup insulin pens are. If the patient started an SGLT-2 inhibitor recently under the new NICE pathway, assume they may not have had full sick day counselling.
SGLT-2 inhibitors in hospital
Withhold SGLT-2 inhibitors in acute illness, for example sepsis, vomiting, dehydration, acute kidney injury or reduced oral intake. Also withhold them in line with local peri-operative policy before surgery or procedures that need fasting.
Check blood ketones, not just glucose. Euglycaemic DKA can occur with near-normal glucose. Nurses should check capillary ketones in any unwell patient on an SGLT-2 inhibitor and escalate raised ketones even when glucose is unremarkable.
Restart deliberately and only once the patient is eating and drinking normally and is clinically stable. Make the restart decision explicit on the discharge prescription so it is not lost or stopped by mistake.
Metformin in hospital
Withhold metformin during acute kidney injury, sepsis, dehydration or significant hypoxia and follow local policy around iodinated contrast. Note the formulation on admission and discharge. With the move to MR metformin, prescribing the wrong formulation by mistake is more likely.
GLP-1 receptor agonists and tirzepatide in hospital
Delayed gastric emptying can increase the risk of aspiration during anaesthesia or sedation. Theatre and anaesthetic teams should know the date of the last dose and follow local peri-operative guidance.
Consider these medicines as a cause of nausea, vomiting or reduced intake on admission. They also add to dehydration risk when combined with an SGLT-2 inhibitor. Watch for hypoglycaemia when a GLP-1 or tirzepatide is combined with insulin or a sulfonylurea, especially when the patient is eating less.
Patients admitted on a hybrid closed loop system
Never leave a person with type 1 diabetes without insulin. If the pump is removed or stops working, start alternative insulin at once. This means subcutaneous basal-bolus insulin or a variable rate intravenous insulin infusion, as clinically appropriate. A gap of only a few hours can lead to DKA.
Assess whether the patient can self-manage. Most patients who are alert and well enough can keep using their system, usually supported by a self-management agreement. Remove the system and switch to ward-based insulin, if the patient is drowsy, confused, critically unwell or in DKA, or cannot operate the device.
Confirm sensor readings with capillary or laboratory glucose before making treatment decisions, especially in critical illness, poor perfusion or hypoglycaemia. Some sensors can also be affected by certain medicines, so check the manufacturer’s information.
Pumps and sensors usually need to be removed before MRI, CT and X-ray and may need consideration with diathermy. Check the manufacturer’s instructions and make sure alternative insulin is in place while the device is off.
On the ward, nurses should document every disconnection and reconnection and keep the patient’s phone or handset charged if it runs the algorithm. Do not discard removed sensors or pumps without the patient’s agreement and make sure hypoglycaemia treatment is at the bedside. Contact the inpatient diabetes team early for any patient on a pump, ideally on the day of admission.
Safe discharge
The discharge letter should make clear which diabetes medicines were withheld, which restarted and which stopped, with reasons. Reinforce sick day rules for SGLT-2 inhibitors, metformin and GLP-1s before the patient leaves.
For hybrid closed loop users, check that the system is working again. Confirm the patient has backup insulin pens, glucose strips and ketone strips at home and tell their specialist diabetes team about the admission.
Key messages for prescribers and nurses
- Newly diagnosed type 2 diabetes now usually starts with two drugs, metformin MR plus an SGLT-2 inhibitor. Make sick day rules and DKA awareness part of the first prescription.
- GLP-1 receptor agonist and tirzepatide eligibility has widened considerably. Review concurrent insulin or sulfonylurea doses and address contraception when prescribing tirzepatide.
- The artificial pancreas is coming to adults. Refer eligible patients and keep backup insulin, glucose strips and ketone strips on repeat.
- In hospital, expect more patients on these therapies. Record the date of the last weekly injection, check ketones in unwell patients on SGLT-2 inhibitors, never leave a pump user without insulin and involve the inpatient diabetes team early.
Pharmacists in the community, in practices and in hospitals are well placed to support these changes. That includes structured medication reviews, medicines reconciliation, peri-operative medicines advice and sick day education.
Prescribers and nurses should refer to the full NICE NG28 guideline, NICE TA943, JBDS-IP inpatient guidance, current SmPCs, the BNF, MHRA safety communications and local formularies, inpatient and peri-operative policies.
Sources
- Pharmaceutical Journal. NICE widens access to SGLT-2 inhibitors and GLP-1s in updated type 2 diabetes guidance. February 2026.
- NHS England. Hybrid closed loop technology.
- Diabetes Times. World-first NHS artificial pancreas rollout helps children with diabetes achieve best glucose levels since records began. May 2026.
- Health Innovation Network. Diabetes UK 2026 and what it means for our national Hybrid Closed Loop programme. May 2026.